RA CAPITAL MANAGEMENT, L.P.
Institutional investor · Portfolio as of Q1 2025
Top Holdings85 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
ASCENDIS PHARMA A/S | 10.3M | $1.6B | 26.8% | $95.48 | +62.01% | 26 qtrssince 2018-Q4 | Increased 63 |
VAXCYTE INC | 12.2M | $460.3M | 7.7% | $49.07 | +41.56% | 20 qtrssince 2020-Q2 | Increased 81 |
RHYTHM PHARMACEUTICALS INC | 6.1M | $322.3M | 5.4% | $25.49 | +115.02% | 26 qtrssince 2018-Q4 | Unchanged 0 |
JANUX THERAPEUTICS INC | 11.2M | $302.1M | 5.0% | $27.88 | +4.38% | 16 qtrssince 2021-Q2 | Increased 65 |
NewAmsterdam Pharma Company N.V. | 10.1M | $207.5M | 3.5% | $14.11 | +54.24% | 10 qtrssince 2022-Q4 | Increased 64 |
ARCELLX INC | 3M | $199.2M | 3.3% | $65.62 | +3.56% | 4 qtrssince 2024-Q2 | Increased 61 |
EDGEWISE THERAPEUTICS INC | 8.9M | $196M | 3.3% | $18.24 | +27.58% | 5 qtrssince 2024-Q1 | Unchanged 0 |
| 6.3M | $186M | 3.1% | $13.96 | +126.32% | 15 qtrssince 2021-Q3 | Unchanged 0 | |
WAVE LIFE SCIENCES LTD | 18.2M | $147.1M | 2.5% | $19.79 | -56.45% | 26 qtrssince 2018-Q4 | Unchanged 0 |
89BIO INC | 19.9M | $144.6M | 2.4% | — | — | 22 qtrssince 2019-Q4 | Increased 69 |
ARS PHARMACEUTICALS INC | 10.9M | $136.6M | 2.3% | $5.93 | +110.72% | 10 qtrssince 2022-Q4 | Unchanged 0 |
SIONNA THERAPEUTICS INC | 10.4M | $109.3M | 1.8% | $11.56 | 0.00% | 1 qtr | New 69 |
LENZ THERAPEUTICS INC | 4.2M | $107.4M | 1.8% | $22.33 | +14.82% | 5 qtrssince 2024-Q1 | Unchanged 0 |
DYNE THERAPEUTICS INC | 9.7M | $101.6M | 1.7% | $23.54 | -51.36% | 5 qtrssince 2024-Q1 | Increased 66 |
TYRA BIOSCIENCES INC | 10.6M | $98.9M | 1.7% | $16.70 | -41.48% | 15 qtrssince 2021-Q3 | Unchanged 0 |
MINERALYS THERAPEUTICS INC | 6.1M | $97.6M | 1.6% | $14.70 | -0.24% | 9 qtrssince 2023-Q1 | Increased 58 |
GERON CORP | 60.4M | $96M | 1.6% | $1.88 | -12.46% | 20 qtrssince 2020-Q2 | Increased 76 |
RXSIGHT INC | 3.7M | $94.5M | 1.6% | $20.41 | +30.11% | 15 qtrssince 2021-Q3 | Unchanged 0 |
BICARA THERAPEUTICS INC | 7M | $90.6M | 1.5% | $25.44 | -47.33% | 3 qtrssince 2024-Q3 | Unchanged 0 |
DISC MEDICINE INC | 1.6M | $78.3M | 1.3% | $52.36 | 0.00% | 1 qtr | New 68 |
RA CAPITAL MANAGEMENT, L.P. manages $6B across 85 positions as of Q1 2025. Top holdings: ASND (26.8%), PCVX (7.7%), RYTM (5.4%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 2/5.0.
Active quarter - 11 new positions, 15 exits, 14 increased. Top move: PCVX (INCREASED, conviction 81). Portfolio: $6.0B across 85 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer